Home » Waxman’s Biogenerics Bill Limits Patent Infringement Damages
Waxman’s Biogenerics Bill Limits Patent Infringement Damages
Brand manufacturers would only be entitled to a “reasonable” royalty when a biogeneric or biosimilar company’s product is found to have infringed on a company’s patents, according to a provision in Rep. Henry Waxman’s (D-Calif.) biogenerics bill. Under House legislation, brand companies would be required to respond to requests from generic companies for information on patents covering their biologic products.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May